Breadcrumb

William L. Dahut, M.D.

William L. Dahut, M.D.

  • Center for Cancer Research
  • National Cancer Institute

RESEARCH SUMMARY

Dr. Dahut left CCR in May 2022. Dr. Dahut’s primary mission was to improve therapy for men with advanced prostate cancer. He pioneered the effort to combine experimental therapies such as angiogenesis and immunotherapy with chemotherapy, androgen blockade, radiotherapy and other more traditional modalities. His recent studies combining immunotherapy with more standard treatment were active and demonstrated the ability to maintain a robust immunologic response. As Section Head, Dr. Dahut oversaw the Branch’s clinical/translational prostate cancer research program, which emphasizes new approaches to the treatment, diagnosis and prognostic evaluation of prostate cancer with the goal to increase the precision in which therapeutic decisions are made for patients with primary and metastatic prostate cancer.

Dr. Dahut also served as Scientific Director for Clinical Research at CCR and as NCI Clinical Director.

Areas of Expertise

1) prostate cancer 2) androgen receptor 3) clinical trials 4) angiogenesis 5) chemotherapy 6) immunotherapy

Information for Patients

Learn more about our clinical trials and the highly specialized care teams that lead them. 

Publications

Selected Key Publications

Neoadjuvant PROSTVAC prior to radical prostatectomy enhances T-cell infiltration into the tumor immune microenvironment in men with prostate cancer

Abdul Sater H, Marté JL, Donahue RN, Walter-Rodriguez B, Heery CR, Steinberg SM, Cordes LM, Chun G, Karzai F, Bilusic M, Harmon SA, Turkbey IB, Choyke PL, Schlom J, Dahut WL, Madan RA, Pinto PA, Gulley JL
J Immunother Cancer. 8(1): e000655, 2020. [ Journal Article ]

How Do We Respond to Men with BRCA Mutations when They Ask About Prostate Cancer?

Karzai F, Madan RA, Dahut WL
Eur Urol. 77(1): 36-37, 2020. [ Journal Article ]

Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations

Karzai F, VanderWeele D, Madan RA, Owens H, Cordes LM, Hankin A, Couvillon A, Nichols E, Bilusic M, Beshiri ML, Kelly K, Krishnasamy V, Lee S, Lee MJ, Yuno A, Trepel JB, Merino MJ, Dittamore R, Marté J, Donahue RN, Schlom J, Killian KJ, Meltzer PS, Steinberg SM, Gulley JL, Lee JM, Dahut WL
J Immunother Cancer. 6(1): 141, 2018. [ Journal Article ]

Phase I Study of a Poxviral TRICOM-Based Vaccine Directed Against the Transcription Factor Brachyury

Heery CR, Palena C, McMahon S, Donahue RN, Lepone LM, Grenga I, Dirmeier U, Cordes L, Marté J, Dahut W, Singh H, Madan RA, Fernando RI, Hamilton DH, Schlom J, Gulley JL
Clin. Cancer Res. 23(22): 6833-45, 2017. [ Journal Article ]

Quantitative Assessment of Early [18F]Sodium Fluoride Positron Emission Tomography/Computed Tomography Response to Treatment in Men With Metastatic Prostate Cancer to Bone

Harmon SA, Perk T, Lin C, Eickhoff J, Choyke PL, Dahut WL, Apolo AB, Humm JL, Larson SM, Morris MJ, Liu G, Jeraj R
J. Clin. Oncol. 35(24): 2829-37, 2017. [ Journal Article ]